Growth Metrics

Axsome Therapeutics (AXSM) Depreciation & Amortization (CF) (2022 - 2026)

Axsome Therapeutics' Depreciation & Amortization (CF) history spans 5 years, with the latest figure at $116000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 22.15% to $116000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $470000.0, a 14.39% decrease, with the full-year FY2025 number at $503000.0, down 5.45% from a year prior.
  • Depreciation & Amortization (CF) hit $116000.0 in Q1 2026 for Axsome Therapeutics, up from $114000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for AXSM hit a ceiling of $149000.0 in Q1 2025 and a floor of $37000.0 in Q1 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $110176.5 across 5 years, with a median of $120000.0 in 2025.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 143.24% in 2023 and later dropped 22.15% in 2026.
  • Tracing AXSM's Depreciation & Amortization (CF) over 5 years: stood at $85000.0 in 2022, then skyrocketed by 56.47% to $133000.0 in 2023, then fell by 3.01% to $129000.0 in 2024, then decreased by 11.63% to $114000.0 in 2025, then grew by 1.75% to $116000.0 in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for AXSM at $116000.0 in Q1 2026, $114000.0 in Q4 2025, and $120000.0 in Q3 2025.